Lanean...
Complement Inhibition for the Treatment of Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80–90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by compl...
Gorde:
| Argitaratua izan da: | Immunotargets Ther |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751298/ https://ncbi.nlm.nih.gov/pubmed/33365280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S261414 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|